Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from the likes of Bristol Myers Squibb.

The biotech had been enrolling patients in a phase 1 trial of a CD19 CAR-T cell therapy called cemacabtagene ansegedleucel—cema-cel for short—for relapsed or refractory chronic lymphocytic leukemia (CLL) in patients previously treated with BTKi and BCL2i therapies.